Ra Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Large Molecule
    • Drug Discovery Technologies
    • Antisense, Oligonucleotides
  • Pharmaceuticals

Other Names/Subsidiaries

  • UCB S.A.
See more in Biomedtracker

Latest on Ra Pharmaceuticals, Inc.

Scrip

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

UCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d

Scrip

With $175m, Mariana Will Take First Precision Radiopharmaceutical Into The Clinic

 
• By Mandy Jackson

Mariana Oncology Inc. CEO Simon Read believes that one of the reasons his company was able to raise the $175m series B venture capital round announced on 7 September was its differentiated approach t

Scrip

UCB Advances Two-Drug Strategy For Myasthenia Gravis

 
• By Joseph Haas

UCB S.A. ’s complement component 5 (C5) inhibitor peptide zilucoplan hit the primary endpoint and two secondary endpoints in a Phase III study in generalized myasthenia gravis (gMG), the firm announce

Scrip

UCB Moves Up Myasthenia Gravis Pipeline With Rozanolixizumab Win

 
• By Kevin Grogan

UCB S.A. has moved closer to becoming a major player in the generalized myasthenia gravis (gMG) space with rozanolixizumab, one of the Belgian group's two late-stage candidates for the rare autoimmun